AR123031A1 - Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo - Google Patents
Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-iloInfo
- Publication number
- AR123031A1 AR123031A1 ARP210102050A ARP210102050A AR123031A1 AR 123031 A1 AR123031 A1 AR 123031A1 AR P210102050 A ARP210102050 A AR P210102050A AR P210102050 A ARP210102050 A AR P210102050A AR 123031 A1 AR123031 A1 AR 123031A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- ylo
- oxadiazole
- formulation
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención proporciona un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, en donde el compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, se administra por vía oral con una dosis total del compuesto de 0,1 mg/día a 5 mg/día, y es útil para tratar una enfermedad neurodegenerativa, incluidas las tauopatías neurodegenerativas, como la enfermedad de Alzheimer, la demencia frontotemporal, el síndrome corticobasilar y la parálisis supranuclear progresiva.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063055362P | 2020-07-23 | 2020-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR123031A1 true AR123031A1 (es) | 2022-10-26 |
Family
ID=77338898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210102050A AR123031A1 (es) | 2020-07-23 | 2021-07-21 | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230338349A1 (es) |
EP (1) | EP4185291A1 (es) |
JP (1) | JP2023535034A (es) |
KR (1) | KR20230043905A (es) |
CN (1) | CN116323604A (es) |
AR (1) | AR123031A1 (es) |
AU (1) | AU2021312894A1 (es) |
BR (1) | BR112023000975A2 (es) |
CA (1) | CA3186808A1 (es) |
CL (1) | CL2023000194A1 (es) |
CO (1) | CO2023000594A2 (es) |
DO (1) | DOP2023000009A (es) |
EC (1) | ECSP23005057A (es) |
IL (1) | IL300023A (es) |
MX (1) | MX2023000993A (es) |
PE (1) | PE20231031A1 (es) |
TW (1) | TW202220650A (es) |
WO (1) | WO2022020663A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023150483A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI654978B (zh) * | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5-甲基-1,2,4-二唑-3-基化合物 |
JP2021530552A (ja) * | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 AU AU2021312894A patent/AU2021312894A1/en active Pending
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko active Search and Examination
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en active Application Filing
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 EP EP21755253.8A patent/EP4185291A1/en active Pending
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
-
2023
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4185291A1 (en) | 2023-05-31 |
BR112023000975A2 (pt) | 2023-02-07 |
CL2023000194A1 (es) | 2023-07-21 |
JP2023535034A (ja) | 2023-08-15 |
KR20230043905A (ko) | 2023-03-31 |
AU2021312894A1 (en) | 2023-02-23 |
PE20231031A1 (es) | 2023-07-10 |
MX2023000993A (es) | 2023-03-01 |
US20230338349A1 (en) | 2023-10-26 |
CN116323604A (zh) | 2023-06-23 |
CO2023000594A2 (es) | 2023-01-26 |
IL300023A (en) | 2023-03-01 |
ECSP23005057A (es) | 2023-02-28 |
WO2022020663A1 (en) | 2022-01-27 |
CA3186808A1 (en) | 2022-01-27 |
DOP2023000009A (es) | 2023-02-15 |
TW202220650A (zh) | 2022-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20210401A1 (es) | Composiciones farmaceuticas que comprenden meloxicam | |
CL2023000167A1 (es) | Péptidos funcionalizados como agentes antivirales | |
ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
CO2021008055A2 (es) | Heterociclos funcionalizados como agentes antivirales | |
PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
PE20030823A1 (es) | Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo | |
UY29827A1 (es) | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones | |
CO5390076A1 (es) | Composiciones farmaceuticas | |
CR20120062A (es) | Terapia combinada para el tratamiento de la diabetes | |
ECSP23005057A (es) | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo | |
BR112015014433A2 (pt) | compostos tricíclicos | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
CL2023000418A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
UY39510A (es) | Compuestos macrocíclicos y métodos para usarlos | |
TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
PE20240881A1 (es) | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t | |
EA202193266A1 (ru) | Антибактериальные производные аминогликозидов | |
DOP2024000018A (es) | Antagonistas del receptor muscarínico 4 y métodos de uso | |
AR122280A1 (es) | Compuestos heterocíclicos antivirales | |
UY39649A (es) | Compuesto para el tratamiento de trastornos cognitivos | |
BR112022008265A2 (pt) | Composições farmacêuticas contendo diácido de oligossacarídeo de alginato |